Baidu
map

Nat Nanotechnol:华人科学家郭培宣教授发明新型RNA纳米技术来“装饰”外泌体可有效抑制肿瘤生长

2017-12-13 Johnny “外泌体之家”微信号

一项新的研究表明,将抗体样(即Y形状)RNA纳米颗粒附着到微泡上可以将有效的RNA治疗剂如小分子干扰RNA(siRNA)特异性地递送给癌细胞。研究人员利用RNA纳米技术来应用RNA纳米颗粒并控制它们的去向,以产生能够在动物模型中成功靶向三种类型癌症的载有治疗剂的细胞外囊泡。该研究结果发表在最新的Nature Nanotechnology杂志上,可促进使用siRNA、microRNA和其他RNA干扰

一项新的研究表明,将抗体样(即Y形状)RNA纳米颗粒附着到微泡上可以将有效的RNA治疗剂如小分子干扰RNA(siRNA)特异性地递送给癌细胞。研究人员利用RNA纳米技术来应用RNA纳米颗粒并控制它们的去向,以产生能够在动物模型中成功靶向三种类型癌症的载有治疗剂的细胞外囊泡。该研究结果发表在最新的Nature Nanotechnology杂志上,可促进使用siRNA、microRNA和其他RNA干扰技术的新一代抗癌药物的开发。该研究由俄亥俄州立大学药学院和俄亥俄州立大学综合癌症中心——詹姆斯癌症医院和索洛夫研究所(OSUCCC-James)的研究人员领导。

该研究通讯作者俄亥俄州立大学药学院讲席教授郭培宣博士说:“使用siRNA和RNA干扰技术的疗法正在改革癌症治疗。但是,由于无法将药物直接输送到人体内的癌细胞,评估这些药物的临床试验却一个接一个地失败了。”

郭教授指出,即使药物到达并进入癌细胞,它们被困在称为胞内体的内部囊泡中,还是没无法发挥效果。

“我们的发现解决了阻碍这些有希望的抗癌治疗方案的两个主要问题:将囊泡靶向递送至肿瘤细胞,并在癌细胞摄取后将治疗剂从胞内体中释放出来。在这项研究中,将这些颗粒全身注射到患有来自人类患者的肿瘤的动物模型后,癌症停止生长。”郭教授说。“我们正在努力将这项技术转化为临床应用。”

郭和他的同事们制备了胞外微泡,这些微泡携带抗体样RNA分子,这种分子被称为适配体,与三种肿瘤类型中的每一种过度表达的表面标志物结合:

1.为了抑制前列腺癌,将囊泡设计成与前列腺特异性膜抗原(PSMA)结合;

2.为了抑制乳腺癌,囊泡被设计为与表皮生长因子受体(EGFR)结合;

3.为了抑制人类来源的结肠直肠癌移植物,将囊泡设计成结合叶酸受体。

作为测试疗法,所有囊泡都装载有用于下调生存素(Survivin)基因的小干扰RNA。生存素基因抑制细胞凋亡,并在许多癌症类型中过表达。

该研究的主要发现包括:

1.靶向前列腺特异性膜抗原的囊泡在动物模型中完全抑制前列腺癌生长,没有观察到毒性。

2.靶向EGFR的囊泡在动物模型中抑制乳腺癌生长。

3.靶向叶酸受体的囊泡在动物模型中显着抑制了人类患者来源的结肠直肠癌的肿瘤生长。

郭教授说:“总的来说,我们的研究表明,RNA纳米技术可以用来编程天然细胞外囊泡,特异性地将干扰RNA传递给癌细胞。”

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2076668, encodeId=5a8520e66681c, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Wed Jul 11 21:23:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061144, encodeId=23b8206114467, content=<a href='/topic/show?id=ccfa6061407' target=_blank style='color:#2F92EE;'>#有效抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60614, encryptionId=ccfa6061407, topicName=有效抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Mon May 07 06:23:00 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882703, encodeId=186c1882e033f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Oct 02 05:23:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652233, encodeId=cc7a16522339b, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat May 05 19:23:00 CST 2018, time=2018-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521251, encodeId=e5611521251dc, content=<a href='/topic/show?id=e96be73835c' target=_blank style='color:#2F92EE;'>#纳米技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77383, encryptionId=e96be73835c, topicName=纳米技术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1e911322397, createdName=windight, createdTime=Fri Dec 15 11:23:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581993, encodeId=d4c4158199333, content=<a href='/topic/show?id=830c35868ec' target=_blank style='color:#2F92EE;'>#华人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35868, encryptionId=830c35868ec, topicName=华人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f7716881423, createdName=ms4468361851264128, createdTime=Fri Dec 15 11:23:00 CST 2017, time=2017-12-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2076668, encodeId=5a8520e66681c, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Wed Jul 11 21:23:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061144, encodeId=23b8206114467, content=<a href='/topic/show?id=ccfa6061407' target=_blank style='color:#2F92EE;'>#有效抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60614, encryptionId=ccfa6061407, topicName=有效抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Mon May 07 06:23:00 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882703, encodeId=186c1882e033f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Oct 02 05:23:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652233, encodeId=cc7a16522339b, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat May 05 19:23:00 CST 2018, time=2018-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521251, encodeId=e5611521251dc, content=<a href='/topic/show?id=e96be73835c' target=_blank style='color:#2F92EE;'>#纳米技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77383, encryptionId=e96be73835c, topicName=纳米技术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1e911322397, createdName=windight, createdTime=Fri Dec 15 11:23:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581993, encodeId=d4c4158199333, content=<a href='/topic/show?id=830c35868ec' target=_blank style='color:#2F92EE;'>#华人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35868, encryptionId=830c35868ec, topicName=华人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f7716881423, createdName=ms4468361851264128, createdTime=Fri Dec 15 11:23:00 CST 2017, time=2017-12-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2076668, encodeId=5a8520e66681c, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Wed Jul 11 21:23:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061144, encodeId=23b8206114467, content=<a href='/topic/show?id=ccfa6061407' target=_blank style='color:#2F92EE;'>#有效抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60614, encryptionId=ccfa6061407, topicName=有效抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Mon May 07 06:23:00 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882703, encodeId=186c1882e033f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Oct 02 05:23:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652233, encodeId=cc7a16522339b, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat May 05 19:23:00 CST 2018, time=2018-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521251, encodeId=e5611521251dc, content=<a href='/topic/show?id=e96be73835c' target=_blank style='color:#2F92EE;'>#纳米技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77383, encryptionId=e96be73835c, topicName=纳米技术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1e911322397, createdName=windight, createdTime=Fri Dec 15 11:23:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581993, encodeId=d4c4158199333, content=<a href='/topic/show?id=830c35868ec' target=_blank style='color:#2F92EE;'>#华人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35868, encryptionId=830c35868ec, topicName=华人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f7716881423, createdName=ms4468361851264128, createdTime=Fri Dec 15 11:23:00 CST 2017, time=2017-12-15, status=1, ipAttribution=)]
    2018-10-02 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=2076668, encodeId=5a8520e66681c, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Wed Jul 11 21:23:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061144, encodeId=23b8206114467, content=<a href='/topic/show?id=ccfa6061407' target=_blank style='color:#2F92EE;'>#有效抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60614, encryptionId=ccfa6061407, topicName=有效抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Mon May 07 06:23:00 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882703, encodeId=186c1882e033f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Oct 02 05:23:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652233, encodeId=cc7a16522339b, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat May 05 19:23:00 CST 2018, time=2018-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521251, encodeId=e5611521251dc, content=<a href='/topic/show?id=e96be73835c' target=_blank style='color:#2F92EE;'>#纳米技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77383, encryptionId=e96be73835c, topicName=纳米技术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1e911322397, createdName=windight, createdTime=Fri Dec 15 11:23:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581993, encodeId=d4c4158199333, content=<a href='/topic/show?id=830c35868ec' target=_blank style='color:#2F92EE;'>#华人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35868, encryptionId=830c35868ec, topicName=华人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f7716881423, createdName=ms4468361851264128, createdTime=Fri Dec 15 11:23:00 CST 2017, time=2017-12-15, status=1, ipAttribution=)]
    2018-05-05 shock_melon
  5. [GetPortalCommentsPageByObjectIdResponse(id=2076668, encodeId=5a8520e66681c, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Wed Jul 11 21:23:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061144, encodeId=23b8206114467, content=<a href='/topic/show?id=ccfa6061407' target=_blank style='color:#2F92EE;'>#有效抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60614, encryptionId=ccfa6061407, topicName=有效抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Mon May 07 06:23:00 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882703, encodeId=186c1882e033f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Oct 02 05:23:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652233, encodeId=cc7a16522339b, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat May 05 19:23:00 CST 2018, time=2018-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521251, encodeId=e5611521251dc, content=<a href='/topic/show?id=e96be73835c' target=_blank style='color:#2F92EE;'>#纳米技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77383, encryptionId=e96be73835c, topicName=纳米技术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1e911322397, createdName=windight, createdTime=Fri Dec 15 11:23:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581993, encodeId=d4c4158199333, content=<a href='/topic/show?id=830c35868ec' target=_blank style='color:#2F92EE;'>#华人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35868, encryptionId=830c35868ec, topicName=华人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f7716881423, createdName=ms4468361851264128, createdTime=Fri Dec 15 11:23:00 CST 2017, time=2017-12-15, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2076668, encodeId=5a8520e66681c, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Wed Jul 11 21:23:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061144, encodeId=23b8206114467, content=<a href='/topic/show?id=ccfa6061407' target=_blank style='color:#2F92EE;'>#有效抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60614, encryptionId=ccfa6061407, topicName=有效抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Mon May 07 06:23:00 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882703, encodeId=186c1882e033f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Oct 02 05:23:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652233, encodeId=cc7a16522339b, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat May 05 19:23:00 CST 2018, time=2018-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521251, encodeId=e5611521251dc, content=<a href='/topic/show?id=e96be73835c' target=_blank style='color:#2F92EE;'>#纳米技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77383, encryptionId=e96be73835c, topicName=纳米技术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1e911322397, createdName=windight, createdTime=Fri Dec 15 11:23:00 CST 2017, time=2017-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581993, encodeId=d4c4158199333, content=<a href='/topic/show?id=830c35868ec' target=_blank style='color:#2F92EE;'>#华人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35868, encryptionId=830c35868ec, topicName=华人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f7716881423, createdName=ms4468361851264128, createdTime=Fri Dec 15 11:23:00 CST 2017, time=2017-12-15, status=1, ipAttribution=)]

相关资讯

Int J Nanomed:透明质酸官能化氧化铋纳米颗粒有助于肿瘤的靶向放疗

临床上由于肿瘤的内在抗性及不准确定位使得其放疗的有效性大大降低,为了克服这些局限性,研究人员使用一锅法合成了透明质酸官能化氧化铋纳米颗粒(HA-Bi2O3 NPs)以用于肿瘤的特异性靶向计算机断层扫描(CT)成像和放射治疗。经透明质酸修饰后,Bi2O3 NPs具有良好的水溶性和良好的生物相容性,且经肿瘤细胞摄取后可过度表达CD44受体。所制备HA-Bi2O3 NPs表现较高的X射线衰减效率高和理想

Ultrasound Med Biol:科学家开发新疗法,在保护健康细胞的同时靶向高效杀灭癌细胞!

包括化疗在内的癌症治疗已经帮助许多患有这种疾病的人过着健康的生活。然而,化疗对身体造成伤害。在治疗期间,化学疗法攻击身体的所有细胞,而不仅仅是癌细胞。结果破坏健康细胞,导致许多患者在治疗期间和治疗后都会发生重大副作用。

Adv Sci:新型siRNA纳米颗粒有效地逆转了肝损伤

RNA干扰(RNAi)作为后基因组时代的一种下调基因表达的工具已被广泛用于基因功能的研究以及疾病的治疗。近年来随着RNA干扰技术在生命领域的应用以及研究的深入,RNA干扰成为了生命科学领域的一个研究热点。小干扰RNA (siRNA)介导的RNA干扰正是通过下调致病基因从而对很多人类疾病实现治疗,如癌症、自身免疫性疾病以及病毒感染性疾病等。但由于siRNA自身的局限性(细胞内不稳定性、肾清除率高、细

Small:光声成像和光热治疗,基于共轭低聚体纳米颗粒的新型光声造影剂和光热材料

近年来,乳腺癌的发病率呈现逐年上升的趋势,引起了人们的广泛关注。其中乳腺癌的淋巴转移是导致患者死亡的主要因素。前哨淋巴结是癌细胞发生淋巴结转移和扩散所必经的第一站,因此前哨淋巴结活检术已经被广泛应用于乳腺外科领域。该技术可以通过切除和活检前哨淋巴结,来判断病理的阳性或阴性,并确定是否采取腋窝淋巴结清扫。而准确探测和定位前哨淋巴结是实施前哨淋巴结活检术的前提条件。目前,最常见的检测示踪方法包括亚甲基

Sci Transl Med:纳米颗粒灌注技术帮助解决器官移植问题

研究人员将纳米颗粒技术和体外灌流 (ex vivo perfusion) 技术结合在一起,能够在体外通过对移植器官进行灌流,将携带治疗器官缺陷药物的纳米颗粒运送到到EC附近。

Int J Oncol:金-大黄酚纳米颗粒可通过失活AKT并诱导细胞凋亡和ROS产生抑制前列腺癌的进展

缓释仍是载药释药的最方便的方法。在本研究中,我们制备了大黄酚金纳米颗粒。将金-大黄酚转化为聚(DL-丙交酯-共-乙交酯)纳米颗粒,测试大黄酚纳米颗粒在人LNCap前列腺癌细胞上的生物活性,及缓释性能。圆二色光谱显示,大黄酚纳米颗粒有效地导致DNA构象改变,并调节与细胞周期停滞相关的不同蛋白质。分析活性氧(ROS)、细胞凋亡、细胞周期、DNA损伤、Cyto-c和caspase-3的活性,并使用免疫印

Baidu
map
Baidu
map
Baidu
map